Clinicopathological features and prognosis in elderly gastric cancer patients: a retrospective cohort study

Guanghui Xu1,*
Fan Feng1,*
Shushang Liu1,*
Fei Wang1,2
Gaozan Zheng1
Qiao Wang1,3
Lei Cai1
Man Guo1
Xiao Lian1
Hongwei Zhang1

1Division of Digestive Surgery, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi’an, Shaanxi, 2Department of General Surgery, No 534 Hospital of PLA, Luoyang, 3Department of Surgery, No 91 Center Hospital of PLA, Jiaozuo, Henan, China

*These authors contributed equally to this work

Background: Little is known about the clinicopathological features and prognosis in elderly gastric cancer (GC) patients aged 65–79 years. The aim of this study was to evaluate clinicopathological features and prognosis in elderly GC patients.

Patients and methods: From May 2008 to December 2014, a total of 5,282 GC patients were enrolled in our present study. Patients were divided into elderly and middle-aged groups. The clinicopathological features and clinical outcomes were analyzed.

Results: The proportion of dysphagia was significantly higher in elderly patients than that in middle-aged patients (P=0.002), whereas the proportion of abdominal pain and heartburn was significantly lower in elderly patients than that in middle-aged patients (P<0.001 vs P=0.038, respectively). The proportion of patients with carbohydrate antigen (CA) 19-9 was significantly higher in elderly patients than that in middle-aged patients (P=0.009). There was no significant difference in clinicopathological features between elderly and middle-aged patients with D2 gastrectomy (all P>0.05). Age, tumor size, histological type, tumor depth, lymph node metastasis, carcinoembryonic antigen, alpha fetoprotein, CA19-9, and CA125 were independent risk factors for the prognosis of GC patients in univariate and multivariate analyses. Overall survival in elderly patients was significantly reduced compared with middle-aged patients (P=0.001), especially in patients with tumor size >5 cm (P=0.002), poorly differentiated tumor (P<0.000), stage III tumor (P=0.002), or normal levels of carcinoembryonic antigen (P=0.009), alpha fetoprotein (P=0.002), CA19-9 (P=0.002), and CA125 (P=0.004).

Conclusion: The clinicopathological features of elderly patients were different to those of middle-aged patients. The prognosis for elderly GC patients was significantly worse than for middle-aged patients.

Keywords: gastric cancer, elderly, clinicopathological features, prognosis

Background: As the world’s population ages, gastric cancer (GC) has become a very common cancer in elderly patients,1,2 especially in patients aged 65 years and older.3,4 Data on the clinicopathological features and prognosis of elderly GC patients are limited and controversial. It was indicated that poorly differentiated tumors were more common in elderly patients.5 However, some studies indicated that younger patients exhibited a predominance of poorly differentiated tumor.6,7 Furthermore, it was reported that the prognosis of GC in the elderly was worse than that in nonelderly patients because of the aggressive biological behavior and poorly differentiated histology of the tumor.8,9 However, Zeeneldin et al9 reported that the prognosis in elderly patients is equivalent to or better than that in nonelderly patients. Moreover, few studies have focused...
specifically on the clinicopathological features and prognosis of GC in elderly and middle-aged patients.

Against this background, we retrospectively analyzed the clinicopathological features and prognosis of elderly and middle-aged GC patients with curative surgical resection. The aim of this study was to identify the clinicopathological features and prognosis of GC in elderly patients.

**Patients and methods**

**Patients and data**

This study was performed in the Xijing Hospital of Digestive Diseases, affiliated with the Fourth Military Medical University. From May 2008 to December 2014, a total of 5,285 consecutive GC patients were enrolled in this study. To compare the prognosis of elderly and middle-aged patients, patients were selected using the inclusion criteria as follows: 1) had undergone a D2 gastrectomy; 2) had no neoadjuvant chemotherapy; 3) had no other type of tumor; and 4) had no distant metastasis.

In the present study, elderly patients were defined as those at the top quartile in the age histogram of GC, whereas middle-aged patients were defined as those within the 10 years range around the second quartile point. The histogram for the 5,285 GC patients is shown in Figure 1, and the top quartile for age included patients older than 65 years. Furthermore, in order to exclude the influence of senility on the overall survival, the elderly patients were defined as those aged 65–79 years. Thus, the elderly group included 815 patients with GC. The second quartile point for age was 58 years, and patients aged 55–64 years were the largest part of the histogram in our department. Therefore, the middle-aged cohort was composed of 1,096 patients aged 55–64 years.

The clinicopathological data including age, gender, tumor location, tumor size, histological type, tumor depth, lymph node metastasis, TNM stage, levels of carcinoembryonic antigen (CEA), alpha fetoprotein (AFP), carbohydrate antigen (CA) 19-9, and CA125 were recorded. The pathological staging was assessed according to the American Joint Committee on Cancer TNM classification of GC (7th edition, 2010). The patients received postoperative chemotherapy according to the NCCN guidelines of GC. A CEA level of ≤5 μg/L, an AFP level of ≤8.1 μg/L, a CA19-9 level of ≤27 U/mL, and a CA125 level of ≤35 μg/mL were considered to be normal. This study was approved by the Ethical Committee of Xijing Hospital, and written informed consent was obtained from all patients. All the patients were followed up twice a year until December 2015.

**Statistical analysis**

Data were processed using SPSS 22.0 for Windows (IBM Corporation, Armonk, NY, USA). Discrete variables were analyzed using the Chi-square test or Fisher’s exact test. Univariate and multivariate analyses were evaluated by Cox’s proportional hazard regression. The overall survival was measured from the time of resection until death or last follow-up. Evaluation for overall survival was obtained by Kaplan–Meier method. P-values <0.05 were considered statistically significant.

**Results**

The clinicopathological features of elderly patients are summarized in Table 1. A total of 5,282 patients were retrospectively analyzed in the study. Among them, 1,381 patients between 65 and 79 years were classified as...
Table 1 Clinicopathological characteristics of middle-aged and elderly gastric cancer patients

| Characteristics                      | Elderly group (n=1,381) | Middle-aged group (n=1,848) | P-value |
|--------------------------------------|-------------------------|-----------------------------|---------|
| Age (years), median (range)          | 69 (65–79)              | 59 (53–64)                  | 0.992   |
| Gender, n (%)                        |                         |                             |         |
| Male                                 | 1,120 (81.10)           | 1,499 (81.11)               |         |
| Female                               | 261 (18.90)             | 349 (18.89)                 |         |
| Abdominal pain, n (%)                |                         |                             |         |
| Negative                             | 631 (45.69)             | 689 (37.28)                 | <0.001  |
| Positive                             | 750 (54.31)             | 1,159 (62.72)               |         |
| Abdominal distension, n (%)          |                         |                             | 0.575   |
| Negative                             | 786 (56.92)             | 1,070 (57.90)               |         |
| Positive                             | 595 (43.08)             | 778 (42.10)                 |         |
| Dysphagia, n (%)                     |                         |                             | 0.002   |
| Negative                             | 1,117 (80.88)           | 1,570 (84.96)               |         |
| Positive                             | 264 (19.12)             | 276 (15.04)                 |         |
| Vomiting, n (%)                      |                         |                             | 0.050   |
| Negative                             | 1,258 (91.09)           | 1,718 (92.97)               |         |
| Positive                             | 123 (8.91)              | 130 (7.03)                  |         |
| Heartburn, n (%)                     |                         |                             | 0.038   |
| Negative                             | 1,180 (85.45)           | 1,529 (82.74)               |         |
| Positive                             | 201 (14.55)             | 319 (17.26)                 |         |
| Melena, n (%)                        |                         |                             | 0.974   |
| Negative                             | 1,249 (90.44)           | 1,672 (90.48)               |         |
| Positive                             | 132 (9.56)              | 176 (9.52)                  |         |
| Surgical procedures, n (%)           |                         |                             | 0.937   |
| Radical operation                    | 1,223 (88.56)           | 1,630 (88.20)               |         |
| Palliative operation                 | 71 (5.14)               | 100 (5.41)                  |         |
| Exploratory operation                | 87 (6.30)               | 118 (6.39)                  |         |
| Tumor location, n (%)                |                         |                             | <0.001  |
| Upper third                          | 524 (37.94)             | 582 (31.49)                 |         |
| Middle third                         | 212 (15.35)             | 371 (20.08)                 |         |
| Lower third                          | 520 (37.65)             | 722 (39.07)                 |         |
| Two-thirds or more                   | 125 (9.05)              | 173 (9.36)                  |         |
| Tumor size (cm), n (%)               |                         |                             | 0.086   |
| <5                                   | 597 (43.23)             | 855 (46.27)                 |         |
| ≥5                                   | 784 (56.77)             | 993 (53.73)                 |         |
| Histologic type (Σ=3,024), n (%)     |                         |                             | 0.472   |
| Well differentiated                  | 182 (14.06)             | 213 (12.31)                 |         |
| Moderately differentiated            | 396 (30.60)             | 526 (30.40)                 |         |
| Poorly differentiated                | 631 (48.76)             | 865 (50.00)                 |         |
| Mucinous or signet ring cell         | 85 (6.57)               | 126 (7.28)                  |         |
| Tumor depth† (Σ=3,024), n (%)        |                         |                             | 0.350   |
| Tis + T1                             | 199 (15.38)             | 300 (17.34)                 |         |
| T2                                   | 207 (16.00)             | 249 (14.39)                 |         |
| T3                                   | 464 (35.86)             | 631 (36.47)                 |         |
| T4                                   | 424 (32.77)             | 550 (31.79)                 |         |
| Lymph node metastasis‡ (Σ=3,024), n (%) | 468 (36.17)     | 617 (35.66)                 | 0.592   |
| N0                                   | 231 (17.85)             | 329 (19.02)                 |         |
| N1                                   | 223 (17.23)             | 317 (18.32)                 |         |
| N3                                   | 372 (28.75)             | 467 (26.99)                 |         |
| TNM stage‡ (Σ=3,108), n (%)          |                         |                             | 0.282   |
| I                                    | 273 (20.57)             | 403 (22.63)                 |         |
| II                                   | 386 (29.09)             | 534 (29.98)                 |         |
| III                                  | 566 (42.65)             | 701 (39.35)                 |         |
| IV                                   | 102 (7.69)              | 143 (8.04)                  |         |

(Continued)

Table 1 (Continued)

| Characteristics                      | Elderly group (n=1,381) | Middle-aged group (n=1,848) | P-value |
|--------------------------------------|-------------------------|-----------------------------|---------|
| CEA (Σ=2,962), n (%)                 |                         |                             | 0.270   |
| Negative                             | 944 (74.92)             | 1,305 (76.67)               |         |
| Positive                             | 316 (25.08)             | 397 (23.33)                 |         |
| AFP (Σ=2,854), n (%)                 |                         |                             | 0.411   |
| Negative                             | 1,142 (94.54)           | 1,544 (93.80)               |         |
| Positive                             | 66 (5.46)               | 102 (6.20)                  |         |
| CA19-9 (Σ=2,892), n (%)              |                         |                             | 0.009   |
| Negative                             | 927 (75.62)             | 1,315 (79.26)               |         |
| Positive                             | 306 (24.38)             | 344 (20.74)                 |         |
| CA125 (Σ=2,808), n (%)               |                         |                             | 0.554   |
| Negative                             | 1,107 (92.33)           | 1,495 (92.91)               |         |
| Positive                             | 92 (7.67)               | 114 (7.09)                  |         |

Notes: *Owing to data acquisition, completeness of data is limited. †Seventh UICC/AJCC TNM classification for gastric cancer.

Abbreviations: AFP, alpha fetoprotein; CA, carbohydrate antigen; CEA, carcinoembryonic antigen; UICC/AJCC, Union for International Cancer Control/American Joint Committee on Cancer.

The risk factors for the prognosis of GC in elderly and middle-aged patients, patients were selected using the inclusion criteria described earlier, which is shown in Figure 2A as a flowchart. Overall, 815 elderly patients and 1,096 patients in the middle-aged group were included. The clinicopathological features of the GC in these elderly and middle-aged patients are summarized in Table 2. There was no significant difference in clinicopathological features between elderly and middle-aged patients (all P>0.05).

In order to further analyze the prognosis between middle-aged and elderly patients, patients were selected using the inclusion criteria described earlier, which is shown in Figure 2A as a flowchart. Overall, 815 elderly patients and 1,096 patients in the middle-aged group were included. The clinicopathological features of the GC in these elderly and middle-aged patients with D2 gastrectomy are summarized in Table 2. There was no significant difference in clinicopathological features between elderly and middle-aged patients (all P>0.05).

The risk factors for the prognosis of GC in elderly and middle-aged patients with D2 gastrectomy were analyzed using univariate and multivariate analyses. The results indicated that age, tumor location, tumor size, histological type, tumor depth, lymph node metastasis, TNM stage, type of
resection, level of CEA, level of AFP, level of CA19-9, and level of CA125 were predictors for overall survival according to the univariate analysis. In addition, age, tumor size, histological type, tumor depth, lymph node metastasis, level of CEA, level of AFP, level of CA19-9, and level of CA125 were independent risk factors for prognosis by multivariate analysis (Table 3). Overall survival in the elderly group was significantly less than that in the middle-aged group (\(P=0.002\), Figure 2B).

As tumor size, histological type, TNM stage, CEA, AFP, CA19-9, and CA125 level were independent risk factors for the prognosis of GC patients, the overall survival between middle-aged and elderly patients was further analyzed within subgroups stratified by the predictors mentioned earlier. The prognosis for elderly patients was significantly worse than that for middle-aged patients with a tumor size \(>5\) cm \(P=0.002\), Figure 3B), poorly differentiated status \((P<0.001,\) Figure 4C), stage III tumor \((P=0.002,\) Figure 5C), normal CEA level \((P=0.009,\) Figure 6A), normal AFP level \((P=0.002,\) Figure 6B), normal CA19-9 level \((P=0.002,\) Figure 6C), and normal CA125 level \((P=0.004,\) Figure 6D). However, the prognosis of elderly patients was comparable to that of middle-aged patients when the tumor size was \(<5\) cm \((P=0.510,\) Figure 3A), with well or moderately differentiated status and mucinous or signet ring cell \((P=0.974,\) \(P=0.566,\) and \(P=0.051,\) respectively, Figure 4A, B, and D), stage I or II tumor \((P=0.407\) or \(P=0.338,\) respectively, Figure 5A and B), elevated CEA level \((P=0.093,\) Figure 6A), elevated AFP level \((P=0.459,\) Figure 6B), elevated CA19-9 level \((P=0.494,\) Figure 6C), and elevated CA125 level \((P=0.183,\) Figure 6D).

**Discussion**

Data on the clinicopathological features and prognosis of elderly GC patients are limited and controversial. In the present study, the clinicopathological features were comparable between elderly and middle-aged GC patients. Age was an independent risk factor for the prognosis of GC, and the prognosis for elderly patients was significantly worse than that for middle-aged patients.

It is widely accepted that the proportion of elderly patients is increasing gradually. Takatsu et al reported that GC usually occurred in individuals aged 60–69 years in Japan. However, our results showed that GC was mainly distributed in patients between 55 and 64 years, which were younger than that in Japan. This may be due to more chronic infection, tobacco smoking, or environmental pollution in China. The definition of elderly varied among previous reports, which have classified aged as \(>70,\) \(>75,\) and \(>80\) years. In our present study, the top quartile of age was \(>65\) years. Moreover, considering the comorbidities associated with very old patients who might influence the prognosis, elderly patients in our present study were defined as those aged 65–79 years. However, the comorbidity in elderly and middle-aged patients and the influence of comorbidity on prognosis were not analyzed in our present study. This requires further investigation.

Previously, the comparison of clinicopathological features has been mainly analyzed between the elderly and young GC patients. However, no study has focused on the clinicopathological features between elderly and middle-aged patients. According to previous reports, the lower third was the most common location for GC in elderly patients. However, tumors located in the upper third were more common in elderly patients in our present study. It is well known that cardiac cancer was associated with gastroesophageal reflux disease (GERD). Moreover, the incidence of GERD increased with age, which was a risk factor for GERD. This may, to some extent, explain the different distribution of tumors in elderly GC patients.
We have confirmed that GC in the elderly is characterized by specific clinicopathological features, including male predominance, poor differentiation, and larger tumor size, which are consistent with previous studies. The reason for male predominance remains unclear. It may be related to the greater susceptibility of male patients to Helicobacter pylori infection, alcohol consumption, and smoking. Infection with H. pylori and alcohol consumption have been associated with an increased risk for GC. In the present study, the proportion of dysphagia was significantly higher and the proportion of abdominal pain were significantly lower in elderly patients than that in the middle-aged group. Patients with stage III tumors comprised 42.65% of elderly patients, which was 13.7%–29.3% reported in previous studies. These may be partially due to hidden clinical manifestations and lack of obvious symptoms in elderly patients with early stage tumors. Moreover, Liang et al reported that the lack of a comprehensive system for tumor screening in China may also result in late diagnosis of GC in elderly patients.

It was reported that positive rates of preoperative serum CEA, AFP, CA19-9, and CA125 tended to be higher in elderly patients than that in nonelderly patients. However, the positive rates of these tumor markers except CA19-9 were not comparable between elderly and middle-aged patients in our present study. This may be a result of differences in race, sample size, and population.

It was reported that the overall survival of elderly patients was significantly less than that of nonelderly patients. In our present study, we also found that age was an independent risk factor for the prognosis of GC patients. However, the prognoses were not comparable between the two groups with tumor sizes <5 cm, well and moderately differentiated status, stage I and II tumors, elevated CEA level, elevated AFP level, elevated CA19-9 level, and elevated CA125 level. These issues require further investigation.

Treatment for elderly GC patients has been criticized. Factors such as comorbidity and decreased functional status may influence the selection of treatment strategies for elderly patients. One of the main concerns with gastrectomy in the elderly is palliative operation or radical dissection. Elderly patients are considered to be high risk for major surgery because of decreasing functional status. Thus, the Japanese guidelines for GC suggest that R0 resection with at least limited lymph node dissection should be considered as the first choice treatment for elderly GC patients. Takeshita et al also reported that limited lymph node dissection in elderly patients did not decrease overall survival of GC patients. However, several studies have reported that complications related surgery could be reduced and prognosis could be improved in elderly patients following advances in surgical and anaesthesiological techniques. Thus, the optimal extent of lymphadenectomy during gastrectomy needs further investigations for elderly GC patients.

Table 2 Clinicopathological characteristics of middle-aged and elderly patients with D2 gastrectomy

| Characteristics                          | Elderly group (n=815) | Middle-aged group (n=1,096) | P-value |
|------------------------------------------|-----------------------|----------------------------|---------|
| Age (years), median (range)              | 70 (65–79)            | 59 (55–64)                 | 0.435   |
| Gender, n (%)                            |                       |                            |         |
| Male                                     | 654 (80.25)           | 895 (81.66)                |         |
| Female                                   | 161 (19.75)           | 201 (18.34)                |         |
| Tumor location, n (%)                    |                       |                            | 0.304   |
| Upper third                              | 325 (39.88)           | 396 (36.13)                |         |
| Middle third                             | 181 (22.21)           | 242 (22.08)                |         |
| Lower third                              | 298 (36.56)           | 444 (40.51)                |         |
| Two-thirds or more                       | 11 (1.35)             | 14 (1.28)                  |         |
| Tumor size (cm), n (%)                   |                       |                            | 0.216   |
| <5                                       | 379 (46.50)           | 541 (49.36)                |         |
| ≥5                                       | 436 (53.50)           | 555 (50.64)                |         |
| Histologic type, n (%)                   |                       |                            | 0.423   |
| Well differentiated                      | 107 (13.13)           | 123 (11.22)                |         |
| Moderate differentiated                  | 252 (30.92)           | 323 (29.47)                |         |
| Poorly differentiated                    | 415 (50.92)           | 587 (53.56)                |         |
| Mucinous or signet ring cell             | 41 (5.03)             | 63 (5.75)                  |         |
| Tumor depth, n (%)                       |                       |                            | 0.623   |
| Tis + T1                                 | 128 (15.71)           | 192 (17.52)                |         |
| T2                                       | 117 (14.36)           | 168 (15.33)                |         |
| T3                                       | 300 (36.81)           | 390 (35.58)                |         |
| T4                                       | 270 (33.13)           | 346 (31.57)                |         |
| Lymph node metastasis, n (%)             |                       |                            | 0.241   |
| N0                                       | 298 (36.56)           | 392 (35.77)                |         |
| N1                                       | 138 (16.93)           | 205 (18.70)                |         |
| N2                                       | 134 (16.44)           | 206 (18.80)                |         |
| N3                                       | 245 (30.06)           | 293 (26.73)                |         |
| TNM stage, n (%)                         |                       |                            | 0.671   |
| I                                        | 185 (22.70)           | 268 (24.45)                |         |
| II                                       | 232 (28.47)           | 306 (27.92)                |         |
| III                                      | 398 (48.83)           | 522 (47.63)                |         |
| Type of resection, n (%)                 |                       |                            | 0.343   |
| Proximal gastrectomy                     | 95 (11.66)            | 126 (11.50)                |         |
| Distal gastrectomy                       | 287 (35.21)           | 421 (38.41)                |         |
| Total gastrectomy                        | 433 (53.13)           | 549 (50.09)                |         |
| CEA, n (%)                               |                       |                            | 0.991   |
| Negative                                 | 633 (77.67)           | 851 (77.65)                |         |
| Positive                                 | 182 (22.33)           | 245 (22.35)                |         |
| AFP, n (%)                               |                       |                            | 0.240   |
| Negative                                 | 774 (94.97)           | 1,027 (93.70)              |         |
| Positive                                 | 41 (5.03)             | 69 (6.30)                  |         |
| CA19-9, n (%)                            |                       |                            | 0.251   |
| Negative                                 | 633 (77.67)           | 875 (79.84)                |         |
| Positive                                 | 182 (22.33)           | 221 (20.16)                |         |
| CA125, n (%)                             |                       |                            | 0.703   |
| Negative                                 | 774 (94.97)           | 1,045 (95.35)              |         |
| Positive                                 | 41 (5.03)             | 51 (4.65)                  |         |

Note: Seventh UICC/AJCC TNM classification for gastric cancer.
Abbreviations: AFP, alpha fetoprotein; CA, carbohydrate antigen; CEA, carcino-embryonic antigen; UICC/AJCC, Union for International Cancer Control/American Joint Committee on Cancer.
Table 3 | Univariate and multivariate analyses of prognostic factors for patients with D2 gastrectomy

| Parameter                  | Univariate analysis |             |             | Multivariate analysis |             |             |
|----------------------------|---------------------|-------------|-------------|-----------------------|-------------|-------------|
|                            | β                   | HR (95% CI) | P-value     | β                     | HR (95% CI) | P-value     |
| Age                        | 0.259               | 1.295 (1.102–1.522) | 0.002       | 0.259                 | 1.296 (1.102–1.524) | 0.002       |
| Gender                     | 0.022               | 1.023 (0.834–1.254) | 0.830       | –                     | –           | –           |
| Tumor location             | –0.093              | 0.911 (0.832–0.996) | 0.042       | –0.001                | 0.999 (0.911–1.096) | 0.989       |
| Tumor size                 | 1.143               | 3.135 (2.616–3.757) | 0.000       | 0.439                 | 1.551 (1.272–1.891) | 0.000       |
| Histologic type            | –0.245              | 0.783 (0.708–0.866) | 0.000       | –0.106                | 0.899 (0.817–0.989) | 0.029       |
| Tumor depth<sup>a</sup>    | 0.827               | 2.287 (2.060–2.539) | 0.000       | 0.469                 | 1.599 (1.363–1.875) | 0.000       |
| Lymph node metastasis<sup>a</sup> | 0.676             | 1.965 (1.824–2.117) | 0.000       | 0.466                 | 1.593 (1.401–1.812) | 0.000       |
| TNM stage<sup>a</sup>      | 1.182               | 3.260 (2.828–3.760) | 0.000       | –0.065                | 0.937 (0.692–1.268) | 0.672       |
| Type of resection          | –0.441              | 0.643 (0.566–0.731) | 0.000       | 0.071                 | 1.073 (0.937–1.228) | 0.306       |
| CEA                        | 0.836               | 2.307 (1.941–2.742) | 0.000       | 0.352                 | 1.424 (1.183–1.715) | 0.000       |
| AFP                        | 0.640               | 1.897 (1.444–2.493) | 0.000       | 0.311                 | 1.365 (1.030–1.809) | 0.030       |
| CA199                      | 0.692               | 1.998 (1.677–2.380) | 0.000       | 0.280                 | 1.324 (1.102–1.591) | 0.003       |
| CA125                      | 1.244               | 3.469 (2.624–4.585) | 0.000       | 0.754                 | 2.125 (1.601–2.821) | 0.000       |

Note: *Seventh UICC/AJCC TNM classification for gastric cancer.

Abbreviations: AFP, alpha fetoprotein; CA, carbohydrate antigen; CEA, carcinoembryonic antigen; HR, hazard ratio; UICC/AJCC, Union for International Cancer Control/American Joint Committee on Cancer.

Figure 3 | Overall survival of patients based on tumor size.

**Note:** The overall survival for elderly and middle-aged patients with tumor size <5 cm (A) and >5 cm (B).

Figure 4 (Continued)
There are some limitations to the present study. First, the retrospective design in a single center might lead to selection bias. Second, the data for comorbidities in elderly and middle-aged patients and the influence of comorbidities on prognosis were not analyzed. These questions require further investigation.

Conclusion
The clinicopathological features of elderly patients were different to those of middle-aged patients. The prognosis of elderly GC patients with D2 gastrectomy was significantly worse than that of middle-aged patients, especially in patients with a tumor of >5 cm, a poorly differentiated tumor,
Figure 6 Overall survival of patients based on tumor markers.

Note: The overall survival for elderly and middle-aged patients with normal and elevated CEA level (A), normal and elevated AFP level (B), normal and elevated CA19-9 level (C), and normal and elevated CA125 level (D).

Abbreviations: AFP, alpha fetoprotein; CA, carbohydrate antigen; CEA, carcinoembryonic antigen.
a stage III tumor, or normal levels of CEA, AFP, CA19-9, or CA125.

**Availability of data and materials**

The data sets supporting the conclusions of this article are included within the article. Data sets cannot be directly shared on public repositories due to the national personal data protection act.

**Acknowledgments**

We wish to thank Shuao Xiao and Xuwen Yang for their help with the collection of data. We express our gratitude to Professor Daming Fan for polishing the article. This study was supported in part by grants from the National Natural Science Foundation of China (nos 81502403, 8167242, 31100643, 31570907, 81572306, and XIZT12Z03).

**Author contributions**

HZ and GX designed and supervised the study. GX, FF, and SL drafted the article. FW, GZ, and LC collected the data and generated the clinical database. QW, MG, and XL interpreted the data and performed the statistical analyses. HZ and FF revised the article. All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Bray F, Jamal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. *Lancet Oncol*. 2012;13(8):790–801.

2. Marugame T, Dongmei Q. Comparison of time trends in stomach cancer incidence (1973–1997) in East Asia, Europe and USA, from cancer incidence in five continents Vol. IV–VIII. *Jpn J Clin Oncol*. 2007;37(3):242–243.

3. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. *CA Cancer J Clin*. 2016;66(2):115–132.

4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer*. 2010;127(12):2893–2917.

5. Lim JH, Lee DH, Shin CM, et al. Clinicopathological features and surgical safety of gastric cancer in elderly patients. *J Korean Med Sci*. 2014;29(12):1639–1645.

6. Wang Z, Xu J, Shi Z, et al. Clinicopathologic characteristics and prognostic factors of gastric cancer in young patients. *Gastric Cancer*. 2016;19(2):472–478.

7. Massaquoi LD, Li M, Wang J, Ma J, Yuan M, Liu DW. Mortality analysis on wastewater exposure in Shijiazhuang, Hebei, China, from 2007 to 2011. *Int J Environ Health Res*. 2015;25(2):214–227.

8. Cao L, Yu J. Effect of *Helicobacter pylori* infection on the composition of gastric microbiota in the development of gastric cancer. *Gastrointest Tumors*. 2015;2(1):14–25.

9. Arai T, Takubo K. Clinicopathological and molecular characteristics of gastric and colorectal carcinomas in the elderly. *Pathol Int*. 2007;57(6):303–314.

10. Kwon IG, Cho I, Guner A, Kim H, Noh SH, Hyung WJ. Minimally invasive surgery as a treatment option for gastric cancer in the elderly: comparison with open surgery for patients 80 years and older. *Surg Endosc*. 2015;29(8):2321–2330.

11. Hsieh FJ, Wang YC, Hsu JT, Liu KH, Yeh CN. Clinicopathological features and prognostic factors of gastric cancer patients aged 40 years or younger. *J Surg Oncol*. 2012;105(3):304–309.

12. Takeshita H, Ichikawa D, Komatsu S, et al. Surgical outcomes of gastrectomy for elderly patients with gastric cancer. *World J Surg*. 2013;37(12):2891–2898.

13. Takeuchi D, Koide N, Suzuki A, et al. Postoperative complications in elderly patients with gastric cancer. *J Surg Res*. 2015;198(2):317–326.

14. Arai T, Esaki Y, Inoshita N, et al. Pathologic characteristics of gastric cancer in the elderly: a retrospective study of 994 surgical patients. *Gastric Cancer*. 2004;7(3):154–159.

15. Mukaisho K, Nakayama T, Gagiwara T, Hattori T, Sugihara H. Two distinct etiologies of gastric cardia adenocarcinoma: interactions among pH, *Helicobacter pylori*, and bile acids. *Front Microbiol*. 2015;6:412.

16. Pattì MG, Waxman I. Gastroesophageal reflux disease: from heartburn to cancer. *World J Gastroenterol*. 2010;16(30):3743–3744.

17. Imagama S, Hasegawa Y, Wakao N, Hirano K, Hamajima N, Ishiguro N. Influence of lumbar kyphosis and back muscle strength on the symptoms of gastroesophageal reflux disease in middle-aged and elderly people. *Eur Spine J*. 2012;21(11):2149–2157.

18. Sakaguchi M, Oka H, Hashimoto T, et al. Obesity as a risk factor for GERD in Japan. *J Gastroenterol*. 2008;43(1):57–62.

19. Saif MW, Makrilia N, Zalonis A, Merikas M, Syrigos K. Gastric cancer in the elderly: an overview. *Eur J Surg Oncol*. 2010;36(8):709–717.

20. Liang YX, Deng JY, Gao HH, et al. Characteristics and prognosis of gastric cancer in patients aged ≥70 years. *World J Gastroenterol*. 2013;19(39):6568–6578.

21. Hwang JJ, Lee DH, Lee AR, et al. Characteristics of gastric cancer in peptic ulcer patients with *Helicobacter pylori* infection. *World J Gastroenterol*. 2015;21(16):4954–4960.

22. Tong GX, Liang H, Chai J, et al. Association of risk of gastric cancer and consumption of tobacco, alcohol and tea in the Chinese population. *Asian Pac J Cancer Prev*. 2014;15(20):8765–8774.

23. Parsonnet J, Friedman GD, Vandersteen DP, et al. *Helicobacter pylori* infection and the risk of gastric carcinoma. *N Engl J Med*. 1991;325(16):1127–1131.

24. Dittmar Y, Rauchfuss F, Gotz M, Scheuerlein H, Jandt K, Settmacher U. Impact of clinical and pathohistological characteristics on the incidence of recurrence and survival in elderly patients with gastric cancer. *World J Surg*. 2012;36(2):338–345.

25. Zhou YC, Zhao HJ, Shen LZ. Preoperative serum CEA and CA19-9 in gastric cancer – a single tertiary hospital study of 1,075 cases. *World J Gastroenterol*. 2012;36(8):709–717.

26. Zeeneldin AA, Ramadan H, ElGM, Saber MM, Elgamal D, Sherisher MA. Gastric carcinoma at Tanta Cancer Center: a comparative retrospective clinico-pathological study of the elderly versus the non-elderly. *J Egypt Natl Canc Inst*. 2014;26(3):127–137.

27. Tong GX, Liang H, Chai J, et al. Association of risk of gastric cancer and consumption of tobacco, alcohol and tea in the Chinese population. *Asian Pac J Cancer Prev*. 2014;15(20):8765–8774.

28. Parsonnet J, Friedman GD, Vandersteen DP, et al. *Helicobacter pylori* infection and the risk of gastric carcinoma. *N Engl J Med*. 1991;325(16):1127–1131.

29. Dittmar Y, Rauchfuss F, Gotz M, Scheuerlein H, Jandt K, Settmacher U. Impact of clinical and pathohistological characteristics on the incidence of recurrence and survival in elderly patients with gastric cancer. *World J Surg*. 2012;36(2):338–345.

30. Zhou YC, Zhao HJ, Shen LZ. Preoperative serum CEA and CA19-9 in gastric cancer – a single tertiary hospital study of 1,075 cases. *Asian Pac J Cancer Prev*. 2015;16(7):2685–2691.

31. Sun Z, Zhang N. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy. *World J Surg Oncol*. 2014;12:397.

32. Chen Y, Qu H, Jian M, Sun G, He Q. High level of serum AFP is an independent negative prognostic factor in gastric cancer. *Int J Biol Markers*. 2015;30(4):e387–e393.
33. Lu J, Huang CM, Zheng CH, et al. Short- and long-term outcomes after laparoscopic versus open total gastrectomy for elderly gastric cancer patients: a propensity score-matched analysis. J Gastrointest Surg. 2015;19(11):1949–1957.
34. Gretschel S, Estevez-Schwarz L, Hunerbein M, Schneider U, Schlag PM. Gastric cancer surgery in elderly patients. World J Surg. 2006;30(8):1468–1474.
35. Thompson A, Cone R, Gao H, Hammond E, Fraser D, Back MF. Is advanced age a barrier to effective cancer treatment? The experience of nonagenarians receiving radiation therapy. Asia Pac J Clin Oncol. 2012;8(3):255–259.
36. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14(2):113–123.
37. Shin HS, Oh SJ, Suh BJ. Factors related to morbidity in elderly gastric cancer patients undergoing gastrectomies. J Gastric Cancer. 2014;14(3):173–179.